Lupus & antiphospholipid syndrome
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study
Authors' conclusion
This study provides real-world experience on the use of ANI in patients with refractory SLE, confirming its rapid effectiveness and an overall acceptable safety profile.
Study context
- Population
- Adults with active refractory systemic lupus erythematosus (SLE), 9 Italian SLE referral centres in a compassionate use program
- Participants
- 26 adults
- Outcome
- Disease activity change from baseline
- Follow-up
- 4 weeks
Methodological detailsmulticentre, real-world, compassionate use program
- Multicentre
- Real-world
- Compassionate use program
Main finding
As reported in the abstract
- Significant decrease in SLEDAI-2K
- P = 0.01
- Significant decrease in SLE-Disease Activity Score
- P = 0.01
- Significant decrease in PGA
- P = 0.001
Observational data: associations, not effects.
Further findings
CLE Disease Area and Severity Index-activity
- Significant reduction
- P < 0.001
Tender and swollen joint counts
- Tender joint count, significant reduction
- P = 0.03
- Swollen joint count, significant reduction
- P = 0.02
Remission and Lupus Low Disease Activity State (LLDAS) · 3 months
- Remission
- 33%
- LLDAS
- 46%
Remission and LLDAS · 6 months
- Remission
- 50%
- LLDAS
- 80%
Nonresponders · at least 24 weeks of follow-up
- Nonresponders among patients with at least 24 weeks of follow-up
- 20%
- 4/20 patients with at least 24 weeks of follow-up
Mean daily glucocorticoid (GC) dose · from week 4
- Significant reduction
- P = 0.04
Safety
| Outcome | Values |
|---|---|
| Disease flares (SELENA-SLEDAI) | ANI 4 events |
- Disease flares (SELENA-SLEDAI) — Mild-moderate flares
- 3
- Disease flares (SELENA-SLEDAI) — Severe flares
- 1
Original publication
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study. J Rheumatol. Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →